GlassScriptPhysician profile
Craig W Spellman
NPI 1174587935
$4,727.55
in general payments reported to CMS, 2019-2025
31 companies · $608 in 2025
The $608 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $471 · 2021: $768 · 2022: $969 · 2023: $771 · 2024: $889 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,268.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $880.73 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $679.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $501.09 | 2019-2025 | Tepezza, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.88 | 2020-2025 | Jardiance, Synjardy |
| Horizon Therapeutics Plc | $331.19 | 2020-2023 | Tepezza |
| Radius Health, INC. | $298.72 | 2020-2025 | Tymlos |
| Tandem Diabetes Care, INC. | $211.10 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ultragenyx Pharmaceutical INC. | $194.07 | 2021-2022 | |
| Insulet Corporation | $139.78 | 2022-2025 | Omnipod |
| Abbott Laboratories | $136.93 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Dexcom, INC. | $122.25 | 2020-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $99.84 | 2020-2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $98.47 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $90.54 | 2019-2024 | |
| Amryt Pharma Holdings LTD | $89.88 | 2021-2023 | Mycapssa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $54.41 | 2023-2025 | Minimed 780g |
| Mannkind Corporation | $48.35 | 2022-2024 | |
| Ascendis Pharma Endocrinology INC | $47.58 | 2023-2025 | Yorvipath |
| Sanofi Pasteur INC. | $39.47 | 2020-2023 | |
| Pfizer INC. | $38.39 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $37.21 | 2024-2025 | Strensiq |
| Soleno Therapeutics, INC. | $33.37 | 2025 | Vykat Xr |
| Beta Bionics, INC. | $29.06 | 2024 | Ilet Bionic Pancreas |
| Astrazeneca Pharmaceuticals LP | $24.93 | 2020 | |
| Echosens North America, INC. | $21.57 | 2023 | Fibroscan |
| Shire North American Group INC | $20.96 | 2019 | |
| Sequel Med Tech, LLC | $20.56 | 2025 | Twiist |
| Esperion Therapeutics, INC. | $15.69 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.12 | 2021 | |
| Chiesi USA, INC. | $15.02 | 2024 | Mycapssa |
| Medtronic Minimed, INC. | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Spellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.